Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BARICITINIB

All products: Limited Use (codes 734)

Other products in the same Health Canada class (L04A) — coverage varies; not interchangeable

  • Tacrolimus (Envarsus PA): limited Use 590
  • Cladribine (Mavenclad): not a benefit

Olumiant · DIN 02544768 · 4mg · tablet

Limited Use — Reason for Use code 734 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 734 required
Write on scriptLU code 734 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 734
Reason for Use code 734 Initiation criteria: For the treatment of adult patients with severe alopecia areata (AA) who meet the following criteria: 1. Have a Severity of Alopecia Tool (SALT) score of 50 or above, and 2. Have experienced the current episode of AA for more than 6 months but less than 8 years. The maximum duration of initial authorization is 36 weeks. Renewal criteria: For continuation of reimbursement, the patient must demonstrate beneficial clinical effect, defined as achieving a SALT score of 20 or less at 36 weeks after treatment initiation. Maintenance of a SALT score of 20 or less every 12 months thereafter is required for reimbursement renewal. Dosing and prescribing: The recommended dose is 2mg once daily. The maximum funded dose is 4mg once daily. Baricitinib should be prescribed by a dermatologist with expertise managing patients with severe AA. Baricitinib should not be used in combination with other JAK inhibitors, biologic immunomodulators, or systemic immunosuppressants. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Olumiant · DIN 02544768 Manufacturer: Eli Lilly Canada Inc.; listing date 2025-12-30 Health Canada: Marketed since 2024-04-09 · brand OLUMIANT · ATC L04AF02 BARICITINIB · form Tablet · route Oral · ingredients BARICITINIB 4 MG · company Eli lilly canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Olumiant: Formulary list price $59.4367/unit (unit not stated in source; not the patient's cost)

Ministry pays: $59.4367 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103336 · Verify on the e-Formulary ↗ (DIN 02544768)

Source record
DIN 02544768: Olumiant Raw flags: sec12=Y, sec3=Y Item: 924400021; group id 1044; item number 2396; lccId 00422; manufacturer id LIL Source form: Tab; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $59.4367; ministry $59.4367 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02544768 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103336
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (92:44 Immunosuppressive Agents) and how they are covered

Matched class: 92:44 Immunosuppressive Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 92:44 Immunosuppressive Agents

TACROLIMUS

· 3 products · Limited Use, codes 590 · strengths: 0.75mg, 1mg, 4mg · ER Tab

CLADRIBINE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:44
Full class listing Related classes: 92:20 Biologic Response Modifiers, 92:36 Disease-Modifying Antirheumatic Agents, 92:92 Other Miscellaneous Therapeutic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: rheumatoid arthritis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ADALIMUMAB · Limited Use, codes 600, 601, 602, 603, 604, 605, 606, 607, 609, 611 (23), Limited Use, codes 600, 602, 603, 604, 605, 606, 607, 609, 633, 634 (7) Indications AMGEVITA is indicated for: Rheumatoid Arthritis • reducing the signs and symptoms, inducing major clinical response and clinical remission, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA). PM: https://pdf.hres.ca/dpd_pm/00085868.PDF; date not captured; DIN 02459299; fetched 2026-09-10 Product monograph METHOTREXATE · General benefit (29), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4) • Severe disabling rheumatoid arthritis (RA) PM: https://pdf.hres.ca/dpd_pm/00078227.PDF; date JAN 08, 2025; DIN 02170698; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS OLUMIANT (baricitinib tablets) is indicated for: Rheumatoid Arthritis (RA) • In combination with methotrexate (MTX), for reducing the signs and symptoms of moderate to severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs). OLUMIANT may be used as monotherapy in cases of intolerance to MTX. Limitations of Use: Use of OLUMIANT in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended (see 7 WARNINGS AND PRECAUTIONS, Immune). Alopecia Areata (AA) OLUMIANT is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use: Use of OLUMIANT in combination with other JAK inhibitors, biologic immunomodulators, or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended (see 7 WARNINGS AND PRECAUTIONS, Immune). 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Cau… https://pdf.hres.ca/dpd_pm/00074394.PDF PM date: not printed or not captured Source product: OLUMIANT; DIN 02480018; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.